Rigor Reviewed

Rigor-Reviewed Manuscript

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.

Name: Αlpha¹ Rigor Record — BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.
Item: BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.
Rating: 100
Author: Αlpha¹

Vu T, Durmus H, Rivner M, Shroff S, Ragole T, Myers B, Pasnoor M, Small G, Karam C, Vullaganti M, Peltier A, Sahagian G, Feinberg MH, Slanksy A, Barnett-Tapia C, Siddiqi Z, Gwathmey K, Badruddoja MA, Kamboh H, Ruggerie RN, Fedak RR, Stewart CA, Kurtoglu M, Kalayoglu M, Singer M, Jewell CM, Miljkovic MD, Dimachkie M, Mozaffar T, Howard JF Jr, MG-001 Study Team

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2★ (Weak), 0 critical, 4 high issues for “BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×6−3★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

References were not verified against Crossref/OpenAlex.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns2

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Implausibly large reported effectAssessed
Other integrity concernAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a methodologically strong, well-reported randomized placebo-controlled phase 2b trial: randomization, blinding, power analysis, ethics approvals, trial registration, data availability, and limitations are all reported adequately, and the 3 machine-checkable statistics recomputed consistently. The main weaknesses are minor reporting inconsistencies (83.0% vs 80.0% month-12 response; 33.0% vs 33.3% MSE) and a few transparency gaps around the modified ITT definition, the MG-ADL-to-MGC endpoint change, and the number screened but not randomized.

Both independent reviewers converged on pass for all eight dimensions; the only intra-checklist divergence was assumptions verified (reported vs not reported), resolved conservatively as not reported without changing the overall pass. The statistics verification covered only 3 tests (those with a test statistic + df or an effect estimate + CI); all other reported statistics were not machine-verified and should be treated as unverified, not confirmed. Citation, reproducibility, preregistration, and claim-audit components returned no integrity flags beyond low-severity internal-consistency notes.

8 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

6 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction reviews the role of BCMA-expressing plasma cells in MG, prior conventional CAR T therapies and their toxicities, and the rationale for a nonintegrating mRNA approach. It acknowledges limitations of existing treatments and prior CAR T approaches, and describes how Descartes-08 addresses them. The hypothesis follows directly from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific foundation, citing prior work on MG pathophysiology, BCMA-targeted CAR T therapy, and the phase 1b/2a results, and logically links these to the trial's objectives.

Evidence

paraphrase[Introduction, paragraphs 1-4]

“Descartes-08 is an autologous BCMA-directed CAR T cell therapy that uses mRNA instead of an integrating viral vector to encode the CAR protein. This feature results in transient targeting and a well-defined pharmacokinetic profile without the risk of unchecked proliferation.”

paraphrase[Introduction, paragraph 3]

“While conventional BCMA-directed CAR T cell therapies—which rely on integrating lentiviral or gamma-retroviral vectors to encode the CAR—involve lymphodepletion chemotherapy that requires intensive postinfusion monitoring, with the potential for acute and delayed toxicity, nonintegrating BCMA-directed CAR T cell therapies may circumvent this toxicity...”

paraphrase[Introduction, paragraph 4]

“In an open-label, multicenter, phase 1b/2a trial of Descartes-08 in gMG (MG-001 parts 1 and 2), patients who received six once-weekly doses without preconditioning chemotherapy in an outpatient setting experienced a robust improvement in gMG symptom severity.”

PASSReviewer 2· 95% conf

The paper clearly establishes the scientific foundation with adequate prior work citations, a logical premise, and discussion of limitations of prior research.

Evidence

direct quote[Introduction, paragraph 3]

“recent studies have suggested that BCMA may be an attractive therapeutic target in gMG”